Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15215MR)

This product GTTS-WQ15215MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF13&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001198622.2; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8741; 10673
UniProt ID Q2QBA2; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15215MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3677MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ1490MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ10254MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ13696MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ10837MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ10178MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ6101MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ3520MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW